Background: Keloids and hypertrophic scars cause physical and psychosocial problems. A combination of 5-fluorouracil (5-FU) and triamcinolone acetonide (TAC) may enhance the treatment of pathologic scars, although the evidence base is limited. The authors compared the efficacy and complication rates of combination intralesional TAC and 5-FU with those of monotherapy intralesional TAC or 5-FU for the treatment of keloids and hypertrophic scars.
Methods: Embase, MEDLINE, and CENTRAL were searched by two independent reviewers. The primary outcome was treatment efficacy (51% to 100% improvement). Study quality and risk of bias were assessed using the Cochrane risk of bias tool.
Results: Of 277 articles screened, 13 studies were included, comprising 12 randomized control trials and one nonrandomized study. Six studies compared combination intralesional therapy versus monotherapy 5-FU, and nine studies compared combination intralesional therapy versus monotherapy TAC. The combined group demonstrated superior objective treatment efficacy compared with the monotherapy TAC group (OR, 3.45; 95% CI, 2.22 to 5.35; I 2 = 0%; P < 0.00001) and monotherapy 5-FU group (OR, 4.17; 95% CI, 2.21 to 7.87; I 2 = 0%; P < 0.0001). Telangiectasia was less frequent in combination therapy (OR, 0.24; 95% CI, 0.11 to 0.52; I 2 = 0%; P = 0.0003) compared with monotherapy TAC.
Conclusions: Combined intralesional TAC and 5-FU administration demonstrated superior treatment efficacy outcomes compared with monotherapy TAC or 5-FU. Patient-reported outcome measures should be incorporated in the design of future research to justify clinical recommendations.
Clinical Relevance Statement: Combined TAC and 5-FU has demonstrated superior treatment efficacy outcomes compared to monotherapy TAC or 5-FU in the treatment of hypertrophic scars and keloids.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PRS.0000000000010867 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy of fractional CO laser with or without triamcinolone acetonide or 5-fluorouracil in the treatment of early postburn hypertrophic scars.
Lasers Med Sci
January 2025
Plastic Surgery Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Hypertrophic scars (HTSs) are the result of an abnormal healing process resulting from burns and other severe traumas. The symptoms of that condition include skin irritation, discomfort, and itching. This study aimed to assess the efficacy of fractional carbon dioxide (CO) laser therapy alone or with triamcinolone or 5-fluorouracil (FU) in the treatment of early post-burn hypertrophic scars (HTSs) that develop during the first 6 months after the injury.
View Article and Find Full Text PDFEfficacy and safety of intralesional triamcinolone acetonide alone and its combination with 5- fluorouracil in keloids and hypertrophic scars: Randomized, parallel group, and double blinded trial.
Skin Health Dis
October 2024
Department of Ophthalmology Maharajgunj Medical Campus Tribhuwan University Kathmandu Nepal.
Article Synopsis
- The study aimed to compare the effectiveness and safety of intralesional triamcinolone acetonide (TAC) alone versus a combination of TAC and 5-fluorouracil (5-FU) in treating keloids and hypertrophic scars over 12 weeks.
- In a randomized trial involving 66 patients, both treatments showed reductions in scar parameters, but the combination therapy demonstrated significantly better results in terms of efficacy, faster response, and fewer complications.
- The findings suggest that while both treatments are viable, the combination of TAC and 5-FU is more effective and safer than TAC alone; however, the study has limitations such as being conducted at a single center and lacking long-term follow-up.
Safety and efficacy of intralesional bleomycin for keloids and hypertrophic scars: A systematic review and meta-analysis.
J Cosmet Dermatol
November 2024
Plastic and Reconstructive Surgery & Burns, Affiliated Hospital of North Sichuan Medical College, Sichuan, Nanchong, China.
Article Synopsis
- Bleomycin, initially an antitumor drug, was researched for treating hypertrophic scars and keloids, with mixed results regarding efficacy and safety among individuals.
- A review of various studies revealed that topical bleomycin was more effective in scar reduction compared to triamcinolone, but showed no significant differences in pigmentation and recurrence rates versus other treatments.
- While bleomycin led to less skin atrophy and telangiectasia, it was associated with increased pain; further studies are needed for a thorough evaluation of its safety and effectiveness.
Myofibroblasts reside in the middle dermis of the keloids but do not predict the response to injection therapies: a double-blinded, randomized, controlled trial.
Front Med (Lausanne)
March 2024
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Introduction: Keloids form as a pathological response to skin wound healing, and their etiopathology is poorly understood. Myofibroblasts, which are cells transformed from normal fibroblasts, are believed to contribute to pathological scar formation in wounds.
Methods: We carried out a double-blinded randomized controlled trial (RCT) comparing the efficacy of intralesional 5-fluorouracil (5-FU) and triamcinolone (TAC) injections in treating keloids.
Comparative Efficacy of Drug Interventions for Keloids: A Network Meta-analysis.
Ann Plast Surg
January 2024
Department of Plastic and Reconstructive Surgery, China Medical University Hospital, Taichung City, Taiwan.
Background: Keloids are common benign skin lesions originating from a disorganized fibroproliferative collagen response; these lesions often lead to both physical and psychological problems. The optimal treatment for keloids is yet to be standardized. Intralesional injection, which is simple and nontraumatic, is one of the most commonly used treatment modalities for these lesions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!